NodThera
@NodThera
Followers
284
Following
195
Media
78
Statuses
121
Treating chronic disease by targeting inflammation at its source
Lexington, MA, USA
Joined April 2019
Today, NodThera is participating in the 5thAnnual Needham Private Biotech and MedTech Company Virtual 1x1 Forum. We look forward to meeting with #investors to discuss our best-in-class pipeline of #NLRP3 #inflammasome inhibitors. Learn more: https://t.co/JrxNh4haPV
0
0
0
Tomorrow, @drjtgeorge M.D., Ph.D., FRCP, FACE, CMO of NodThera will present on the “Obesity & Related Conditions Panel: Advanced Therapeutics” at the 25thAnnual Biotech in Europe Forum (#Sachs_BEF) hosted by @SachsAssociates. Learn more: https://t.co/b0icitJOJw
0
0
0
On #WorldHeartDay, we’re highlighting our commitment to treating #cardiovascular (CV) diseases. Learn more about our clinical trial in patients with #obesity and CV risk, and how our targeted approach is re-imagining how these diseases are treated: https://t.co/j6PJ0dwxLE
0
1
2
We're excited to attend the Obesity Science & Innovation Congress! Nick Clarke, Ph.D., NodThera’s Chief Development Officer, will present an overview of our novel approach to #obesitytherapeutics. Learn more about our science: https://t.co/9cIrvaH90O
0
0
0
Great to see our CEO Daniel Swisher in conversation with @BiotechTVHQ yesterday, discussing progress within our #pipeline of #NLRP3 #inflammasome inhibitors and their potential to transform treatment of diseases driven by chronic low-grade #inflammation
https://t.co/AjNwxd9Ejj
biotechtv.com
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a...
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: On a visit through London today, @NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss. Full video: https://t.co/c6FSG8Baym
0
0
3
Register now to hear our CEO, Dan Swisher, speak on the potential of NT-0796, our lead #NLRP3 #Inflammasome inhibitor, to deliver sustained and healthy weight loss in a #FireSideChat at the @Piper_Sandler Virtual #Obesity Symposium with ADA Takeaways: https://t.co/YXDX6uWvbS
0
0
0
Please join us in welcoming Elisabeth Björk to NodThera’s Board of Directors! Elisabeth brings more than 20 years of pharmaceutical #leadership experience, with key areas of strength in #obesity and cardiometabolic disease. For more: https://t.co/Nii0Ft0yf4
0
0
0
In a new article in MedNous, Alan Watt, President & Chief Scientific Officer, discusses our recently initiated Phase 2 RESOLVE-1 #ClinicalTrial, evaluating #NLRP3 #inflammasome inhibitor NT-0796 in patients with #obesity: https://t.co/KwBPMWhnqf
#Biotech #NodThera #Innovation
0
0
0
We have reached a major milestone, dosing the first patients in our Phase 2 RESOLVE-1 #ClinicalTrial investigating the potential of our lead candidate and oral #NLRP3 #inflammasome inhibitor, NT-0796. Read the full announcement here: https://t.co/gg12O7Wh4V
0
0
2
New data has been published in the #research journal Obesity (@ObesitySociety), demonstrating the potential of NT-0796, our oral #NLRP3 #inflammasome inhibitor, to induce healthier and sustained weight loss in combination with GLP-1 receptor agonist: https://t.co/iGoV9ulN8x
0
0
1
NodThera will participate in a #FiresideChat at the 2ndAnnual @Piper_Sandler Virtual Cardio Symposium, held from 1-2 April. Join to learn more about our pioneering #NLRP3 #inflammasome targeting approach for the treatment of conditions driven by chronic #inflammation. #biotech
0
0
0
On 27 March, David Harrison, VP, Medicinal Chemistry, will presenting at the #ACSSpring2025 Meeting & Expo. Be sure to stop by to learn more about the journey of lead brain-penetrant #NLRP3 #inflammasome inhibitor NT-0796 from discovery through to #ClinicalDevelopment. #Biotech
0
0
1
Meet us at BIO-Europe Spring next week! Excited to connect on NodThera’s #NLRP3 #inflammasome inhibitors, tackling chronic inflammation at it’s source. Let’s meet in Milan! #NodThera #BioEuropeSpring #Networking #Conference #Biotech
0
0
0
NodThera’s management team will be in Miami on 10 March to participate in 1-1 #investor meetings at the Leerink Partners 2025 Global #Healthcare Conference. If you would like to learn more about our work, please reach out to set up a meeting. #Inflammation #NLRP3 #biotech
0
0
0
Our CEO, Dan Swisher, recently sat down with @trinitychavez, Lead Anchor at @NYSE, to share our plans for 2025. To learn more, watch the full conversation on #TakingStock: https://t.co/I3ICG8kWtq
#NLRP3 #Inflammation #Inflammasome
0
0
1
Our CEO, Dan Swisher, will be participating in a panel discussion and 1-1 meetings at the Guggenheim SMID Cap #Biotech #Conference in New York City on 6 February. Please get in touch if you would like to connect. #NLRP3 #Inflammasome #Inflammation
0
0
1
Dan Swisher, CEO, will participating in the 'BioPharma Dealmaking: Building the Pipeline' panel alongside leading #BioPharma experts at #Sach_BOIF. Join him to learn more about the key strategies shaping the #obesity treatment space: https://t.co/hnnSMwtRrx
#Conference #NLRP3
0
0
1
This year highlighted the broad therapeutic promise of brain-penetrant #NLRP3 #inflammasome inhibitors. Our VP of Medicinal Chemistry, David Harrison shares insights in #JMedChem on this evolving therapeutic landscape. Read here:
pubs.acs.org
The NLRP3 inflammasome has attracted much interest as a drug target; however, many of the first wave of inhibitors were derived from a single aryl sulfonylurea starting point. The physicochemical...
0
2
4
NodThera has been featured in @Citeline 's latest article on obesity and the current innovative approaches to obesity treatment. Read the full article here: https://t.co/32Ltcvdrjg
#NodThera #Obesity #Inflammation #Innovation
0
1
3
Excited to attend the @Piper_Sandler 36th Annual Healthcare Conference, held from 3-5 Dec in NYC! We’ll share how #NodThera’s #NLRP3 inflammasome inhibitors are transforming #cardiometabolic & #neurodegenerative disease treatment. Let’s connect! #Networking #Inflammation
0
0
1